Enliven Therapeutics
Develops small-molecule therapies centered on ELVN-001 for chronic myeloid leukemia.
$57.69
After-hours close−0.16 (−0.27%)
At close$57.85(−4.38%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 116.53%Insiders 2.99%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 71.44M · Float 45.61M · 63.9% free float
Institutions13F, as of Jun 30, 2026
220 holders · 83.25M shares · 65 new positions · 154 increased · 49 reduced · 21 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 10.03M | 14.03% | +3.20M | Aug 13, 2026 |
| Orbimed Advisors LLC | 6.78M | 9.49% | −1.18M | Aug 14, 2026 |
| Polar Capital Holdings PLC | 6.43M | 9.00% | +1.36M | Aug 14, 2026 |
| BlackRock, Inc. | 4.36M | 6.10% | +675.0K | Aug 7, 2026 |
| Vestal Point Capital, LP | 4.00M | 5.60% | +750.0K | Aug 14, 2026 |
| Commodore Capital LP | 3.28M | 4.58% | 0 | Aug 14, 2026 |
| Price T Rowe Associates Inc /MD/ | 2.90M | 4.06% | +2.81M | Aug 14, 2026 |
| Vanguard Capital Management LLC | 2.57M | 3.60% | +400.8K | Aug 13, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 13.30% | 7.87M | 13G | Nov 5, 2025 ↗ |
| Orbimed Advisors LLCincl. Orbimed Capital GP Vii LLC, Orbimed Capital LLC +1 more | 9.50% | 6.77M | 13D | Jun 24, 2026 ↗ |
| Polar Capital Holdings Plc | 8.46% | 5.06M | 13G | Jun 22, 2026 ↗ |
| Commodore Capital LP | 7.70% | 4.80M | 13G | May 15, 2026 ↗ |
| Polar Capital LLPincl. Polar Capital Holdings Plc | 5.69% | 2.69M | Nov 13, 2024 ↗ | |
| Vestal Point Capital, LP | 5.40% | 3.25M | 13G | May 15, 2026 ↗ |
| BlackRock, Inc. | 5.10% | 2.94M | 13G | Jul 17, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Samuel Kintz | director, officer: PRESIDENT AND CEO | 890.4K | 1.25% | Nov 19, 2025 |
| Joseph P. Lyssikatos | officer: CHIEF SCIENTIFIC OFFICER | 758.9K | 1.06% | Feb 17, 2026 |
| Anish Patel | officer: CHIEF OPERATING OFFICER | 235.0K | 0.33% | Feb 17, 2026 |
| Orbimed Advisors LLC | 10 percent owner | 219.4K | 0.31% | Jun 24, 2026 |
| Richard A. Heyman | director | 146.3K | 0.20% | Feb 19, 2026 |
| Lori Anne Kunkel | director | 41.9K | 0.06% | Jul 8, 2026 |
| Benjamin Hohl | officer: CHIEF FINANCIAL OFFICER | 40.0K | 0.06% | Aug 19, 2026 |
| Helen Louise Collins | officer: CHIEF MEDICAL OFFICER | 25.0K | 0.03% | Aug 19, 2026 |
3 ten-percent owners hold 2.98M shares by Form 4 — the 13D/G table above shows those stakes, the figure above counts officers and directors only · 2 people have not refiled in the last 18 months (277.2K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 17, 2026 | Helen Louise Collinsofficer: CHIEF MEDICAL OFFICER | Sale · 2 lots | 5,000 | $58.59 | 25,000 |
| Aug 17, 2026 | Benjamin Hohlofficer: CHIEF FINANCIAL OFFICER | Sale · 2 lots | 6,018 | $58.58 | 40,036 |
| Aug 4, 2026 | Mika K. Derynckdirector | Sale | 158,795 | $60.21 | 0 |
| Jul 17, 2026 | Helen Louise Collinsofficer: CHIEF MEDICAL OFFICER | Sale · 5 lots | 5,000 | $52.67 | 25,000 |
| Jul 17, 2026 | Benjamin Hohlofficer: CHIEF FINANCIAL OFFICER | Sale · 5 lots | 6,018 | $52.64 | 46,054 |
| Jul 6, 2026 | Lori Anne Kunkeldirector | Sale · 2 lots | 10,000 | $50.49 | 41,884 |
| Jun 22, 2026 | Orbimed Advisors LLC10 percent owner | Sale · 4 lots | 860,123 | $45.36 | 219,405 |
| Jun 17, 2026 | Helen Louise Collinsofficer: CHIEF MEDICAL OFFICER | Sale · 3 lots | 5,000 | $43.80 | 25,000 |
| Jun 17, 2026 | Benjamin Hohlofficer: CHIEF FINANCIAL OFFICER | Sale · 3 lots | 6,018 | $43.80 | 51,000 |
| Jun 15, 2026 | Orbimed Advisors LLC10 percent owner | Sale · 2 lots | 281,408 | $45.02 | 245,728 |
CongressHouse and Senate disclosures
Not reported.